dc.contributor.author | Schifano, Fabrizio | |
dc.contributor.author | Chiappini, Stephania | |
dc.contributor.author | Corkery, John Martin | |
dc.contributor.author | Scherbaum, Norbert | |
dc.contributor.author | Guirguis, Amira | |
dc.date.accessioned | 2021-04-23T23:06:54Z | |
dc.date.available | 2021-04-23T23:06:54Z | |
dc.date.issued | 2021-04-01 | |
dc.identifier.citation | Schifano , F , Chiappini , S , Corkery , J M , Scherbaum , N & Guirguis , A 2021 , ' The e-psychonaut drugs’ psychopharmacology ' , Current Opinion in Pharmacology , vol. 57 , pp. 165-174 . https://doi.org/10.1016/j.coph.2021.02.008 | |
dc.identifier.issn | 1471-4892 | |
dc.identifier.uri | http://hdl.handle.net/2299/24307 | |
dc.description | © 2021 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1016/j.coph.2021.02.008 | |
dc.description.abstract | The focus here was on the pharmacological and clinical pharmacological issues pertaining to the vast range of drugs (e.g. synthetic cannabimimetics, synthetic opioids, novel stimulants, novel psychedelics, PCP/ketamine-like compounds, prescribed medicinal compounds and popular psychotropic herbs/plants) discussed by Internet-based enthusiasts of new/novel psychoactive substances (NPS), ‘e-psychonauts’. Currently ongoing related in silico studies, followed by further in vitro and in vivo/preclinical studies, will hopefully provide important findings in terms of which molecules within each given NPS class may present with higher levels of receptor affinities, and hence clinical potency. Understanding the pharmacological characteristics/potency of those novel recreational molecules will hopefully help in predicting related NPS diffusion, morbidity and possible lethality data. | en |
dc.format.extent | 10 | |
dc.format.extent | 301437 | |
dc.language.iso | eng | |
dc.relation.ispartof | Current Opinion in Pharmacology | |
dc.subject | e-psychonauts | |
dc.subject | psychopharmacology | |
dc.subject | addiction | |
dc.subject | new psychoactive substances | |
dc.subject | novel psychoactive substances | |
dc.subject | NPS | |
dc.subject | drug abuse | |
dc.subject | Drug abuse | |
dc.subject | Novel psychoactive substances | |
dc.subject | Addiction | |
dc.subject | Psychopharmacology | |
dc.subject | New psychoactive substances | |
dc.subject | Drug Discovery | |
dc.subject | Pharmacology | |
dc.title | The e-psychonaut drugs’ psychopharmacology | en |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.description.status | Peer reviewed | |
dc.date.embargoedUntil | 2022-03-25 | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85103392795&partnerID=8YFLogxK | |
rioxxterms.versionofrecord | 10.1016/j.coph.2021.02.008 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |